Omega-3 fatty acids and their rapidly evolving role in the management of psychiatric disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 2014-2015

  Kapoor, Shailendra ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; NEUROTROPHIN RECEPTOR; OMEGA 3 FATTY ACID; SEROTONIN UPTAKE INHIBITOR;

AGITATION; BIPOLAR DISORDER; BRAIN ATROPHY; COGNITION; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFICACY; HUMAN; LETTER; MENTAL DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PUERPERAL DEPRESSION; RISK FACTOR; SCHIZOPHRENIA; TREATMENT OUTCOME;

FATTY ACIDS, ESSENTIAL; FATTY ACIDS, OMEGA-3; HUMANS; MENTAL DISORDERS;

EID: 56449083403     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.08.006     Document Type: Letter

References (13)

1. Buydens-Branchey L., and Branchey M. Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. Psychiatry Res 157 (2008) 95-104
2. Chiu C.C., Su K.P., Cheng T.C., et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 1538-1544
3. Feart C., Peuchant E., Letenneur L., et al. Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr 87 (2008) 1156-1162
4. Freeman M.P., Hibbeln J.R., Wisner K.L., Brumbach B.H., Watchman M., and Gelenberg A.J. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113 (2006) 31-35
5. Freund-Levi Y., Basun H., Cederholm T., et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 23 (2008) 161-169
6. Jazayeri S., Tehrani-Doost M., Keshavarz S.A., et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 42 (2008) 192-198
7. Kou W., Luchtman D., and Song C. Eicosapentaenoic acid (EPA) increases cell viability and expression of neurotrophin receptors in retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cells. Eur J Nutr 47 (2008) 104-113
8. McNamara R.K., Sullivan J., and Richtand N.M. Omega-3 fatty acid deficiency augments amphetamine-induced behavioral sensitization in adult mice: prevention by chronic lithium treatment. J Psychiatr Res 42 (2008) 458-468
9. Osher Y., Bersudsky Y., and Belmaker R.H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 66 (2005) 726-729
10. Peet M. Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia. Isr J Psychiatry Relat Sci 45 (2008) 19-25
11. Puri B., Bydder G., Clarke A., Manku M., and Beckmann C. Reduction in brain atrophy associated with ethyl-eicosapentaenoic acid in patients with Huntington's disease. European Psychiatry 23 (2008) 196
12. Vaisman N., Kaysar N., Zaruk-Adasha Y., et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 87 (2008) 1170-1180
13. Vancassel S., Leman S., Hanonick L., et al. n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J Lipid Res 49 (2008) 340-348